Project Grant K99CA307864
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $151K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $137,631 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to Sloan-Kettering Institute for Cancer Research, effective July 3, 2026, with a completion date of June 30, 2028. This award supports biomedical research training and investigation into the mechanisms by which somatic mutations in RNA splicing factor genes (U2AF1, SF3B1, and SRSF2) drive the development of myelodysplastic syndromes...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded $140,400 to Sloan-Kettering Institute for Cancer Research under the Cancer Research Manpower program (CFDA 93.398) to develop artificial intelligence (AI)-based methods that integrate genomic and histopathologic data to advance precision cancer medicine. This Project Grant, awarded July 17, 2026, and scheduled for completion by June 30, 2028, funds research focused on creating multimodal, interpretable AI models that combine...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $294,451 Project Grant on June 5, 2026, under the Cancer Research Manpower program (CFDA 93.398) to Sloan-Kettering Institute for Cancer Research to support cancer research training and workforce development. This career development award funds Dr. Narendra's research program investigating the mechanisms by which somatic mutations in the E1 ubiquitin-activating enzyme (UBA1) drive VEXAS (vacuoles, E1 enzyme, X-linked,...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $323,860 to Sloan-Kettering Institute for Cancer Research on August 18, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support research investigating the role of mutagenic DNA repair during cancer cell persistence. The research will examine how cancer cells under stress from anti-cancer drug exposure shift their reliance from error-free DNA repair pathways—such as homologous recombination (HR)—to...
- Federal Grant Award Summary The National Cancer Institute awarded a $736,168 Project Grant to Sloan-Kettering Institute for Cancer Research (award date: August 1, 2025; completion date: July 31, 2030) under the Cancer Treatment Research program (CFDA 93.395) to develop novel antibody-drug conjugates (ADCs) and antibody-oligonucleotide conjugates (AOCs) designed to enhance radiotherapy efficacy through antigen-specific radiosensitization. The research focuses on delivering potent DNA damage...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $418,176.00 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2028. This three-year award supports the advanced development and validation of programmable nucleic acid cytometry, a technology designed to isolate and profile rare cell populations from tumors and tissues. Building on the...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $246,362 to the Sloan-Kettering Institute for Cancer Research under the Cancer Research Manpower program (CFDA 93.398) on June 12, 2026, with a completion date of May 31, 2031. This Project Grant funds research to elucidate the mechanisms by which homologous recombination deficiency (HRD), particularly BRCA2 mutations, affects estrogen receptor-positive (ER+) breast cancer responsiveness to endocrine therapy. The...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Sloan-Kettering Institute for Cancer Research a Project Grant of $671,252 under the Cancer Biology Research program (CFDA 93.396), effective July 1, 2026, through June 30, 2031. This five-year research initiative investigates the mechanisms by which CD4 T cells and dendritic cells (DC) work in concert with CD8 T cells to enhance anti-tumor immunity. Specifically, the research focuses on understanding how...
- The National Cancer Institute (NCI) awarded Columbia University's Health Sciences Division a $155,052 Project Grant under the Cancer Research Manpower program (CFDA 93.398) on December 25, 2025, with a completion date of June 30, 2028. This award supports research training and workforce development in cancer research aligned with the National Cancer Program. The funding enables biomedical training opportunities for individuals pursuing careers in basic, clinical, and prevention research at the...
- Federal Project Grant Award Summary The National Cancer Institute awarded $1,034,176 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 18, 2025, for a project extending through July 31, 2032. The research focuses on understanding and targeting aberrant RNA splicing in leukemia, building on the principal investigator's 13-year track record of discovering genetic alterations in hematopoietic malignancies. The project aims to...